SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Income Before Tax

Profit after all operating and non-operating items but before income tax.

SNDL Inc.NASDAQ: SNDL

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -CA$11.41M, compared with -CA$14.71M a year earlier. Trailing-twelve-month income before tax was -CA$12.48M.

Context

  • Income before tax amounted to 1.7% of revenue in FY2025, down 9.8 pp from a year earlier.
  • Income before tax grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -CA$11.41M or moves back toward the trailing-twelve-month quarterly average of -CA$3.12M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$11.41M-221.8% QoQ
Last fiscal yearDec 2025
-CA$15.77M+85.1% YoY
LTMMar 2026
-CA$12.48M+88.9% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.4%——
1 year+85.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

CAD · from the income statement

Latest · FY2025
(15.77M) CAD
Year-over-year change
+85.1%

Income Before Tax vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +88.9% is the 4th highest of 11, against a peer median of +8.3%.
  • Income before tax amounts to 1.3% of revenue for SNDL, versus a peer median of 8.1%.
SNDL Competitors
Income Before Tax for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SIGASIGA Technologies, Inc.LTM Mar 2026$26.93M USD-56.8%-11.7%28.7%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$4.28M USD+117.7%+32.3%0.8%
EBSEmergent BioSolutions Inc.LTM Mar 2026$3.5M USD+105.6%—0.5%
ESPREsperion Therapeutics, Inc.LTM Mar 2026-$5.58M USD+96.4%—1.3%
SNDLSNDL Inc.LTM Mar 2026-CA$12.48M CAD+88.9%—1.3%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-$18.76M USD+58.6%—8.1%
EOLSEvolus, Inc.LTM Mar 2026-$42.56M USD+23.3%—14.1%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$44.17M USD-6.7%——
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-$68.91M USD-27.0%—137.1%
CMPSCOMPASS Pathways plcLTM Mar 2026-$184.26M USD-35.4%——
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$185.15M USD-43.6%——
Peer median (excluding SNDL) —+8.3%+10.3%8.1%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.13M712.2M909.01M920.45M946.4M
Cost of Revenue65.13M571.82M718.59M680.12M687.75M
Gross Profit(9M)140.38M190.42M240.33M258.65M
Gross Margin-16.0%19.7%20.9%26.1%27.3%
Research & Development2.45M2.45M324K346K489K
Selling, General & Admin55.39M158.26M230.17M219.28M210.63M
Operating Expenses125.38M488.15M353.59M344.14M263.07M
Depreciation & Amortization10.16M47.32M64.95M56.71M56.27M
EBITDA(223.76M)(326.55M)(99.15M)(41.2M)48.02M
EBITDA Margin-398.7%-45.9%-10.9%-4.5%5.1%
Operating Income(134.38M)(347.77M)(163.17M)(103.81M)(4.42M)
Operating Margin-239.4%-48.8%-18.0%-11.3%-0.5%
Interest Income13.72M17.62M15.37M16.4M8.05M
Interest Expense776K5.9M7.92M7.7M7.52M
Other Income / Expenses(100.32M)(32M)(8.85M)(1.8M)(11.35M)
Income Before Tax(234.7M)(379.77M)(172.02M)(105.61M)(15.77M)
Pre-Tax Margin-418.1%-53.3%-18.9%-11.5%-1.7%
Income Tax Expense(7.91M)(7.34M)0(9.41M)0
Net Income(226.98M)(335.11M)(172.66M)(94.8M)(15.77M)
Net Margin-404.4%-47.1%-19.0%-10.3%-1.7%
EPS (Basic)(1.24)(1.50)(0.65)(0.38)(0.06)
EPS (Diluted)(1.24)(1.50)(0.65)(0.38)(0.06)
Weighted Avg Shares186.04M229.87M259.37M264.2M258.05M
Weighted Avg Shares (Diluted)186.04M229.87M259.37M264.2M258.05M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.